Eltanexor Plus Inqovi
A Phase I/II Trial of Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 80 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- Chemotherapy, Cytidine Deaminase Inhibitor (CDAi), Nucleoside Metabolic Inhibitor, Selective Inhibiton of Nuclear Export (SINE)
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1733
- NCT Identifier
- NCT05918055
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.